This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Innovative and adaptive strategies for new drug development are needed to maximize the potential of cell and gene therapies. CRA’s Lev Gerlovin with co-authors Walter Colasante and Pascale Diesel explain in this Cell and Gene article. Click here to read the article.
These entities receive discounts on all eligible covered outpatient drugs. The program has expanded substantially over the years, with the number of covered...
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...
CRA is a proud sponsor of the Educational Symposia session titled “The Oncology Combination Therapy Dilemma: Can Today’s HTA Systems Support Tomorrow’s...
CRA is a proud sponsor of the conference. Greg Bell speaks during the session titled “Damages in Pharma & Biotech Litigation: What Courts are Accepting...
